期刊
JOURNAL OF CONTROLLED RELEASE
卷 337, 期 -, 页码 612-627出版社
ELSEVIER
DOI: 10.1016/j.jconrel.2021.07.044
关键词
Inflammatory neutrophil recognition; Sialic acid conjugate; Liposome; Doxorubicin; Neutrophil-related inflammation; Immune homeostasis
资金
- National Natural Science Foundation of China [81973271, 81703456]
- Disruptive Technology Innovation Guidance Fund of Shenyang Pharmaceutical University [51120666]
The study demonstrated the effectiveness and safety of using sialic acid-modified liposomal doxorubicin to selectively target inflammatory neutrophils, suppressing the inflammatory response in various disease models. This targeted nanocarrier drug delivery system shows potential as a revolutionary treatment strategy for inflammatory diseases caused by inappropriate neutrophil activation.
Neutrophils, the most abundant leukocytes in human peripheral blood, are important effector cells that mediate the inflammatory response. During neutrophil dysfunction, excessive activation and uncontrolled infiltration are the core processes in the progression of inflammation-related diseases, including severe coronavirus disease-19 (COVID-19), sepsis, etc. Herein, we used sialic acid-modified liposomal doxorubicin (DOX-SAL) to selectively target inflammatory neutrophils in the peripheral blood and deliver DOX intracellularly, inducing neutrophil apoptosis, blocking neutrophil migration, and inhibiting the inflammatory response. Strong selectivity resulted from the specific affinity between SA and L-selectin, which is highly expressed on inflammatory neutrophil membranes. In inflammation models of acute lung inflammation/injury (ALI), sepsis, and rheumatoid arthritis (RA), DOX-SAL suppressed the inflammatory response, increased the survival of mice, and delayed disease progression, respectively. Moreover, DOX-SAL restored immune homeostasis in the body, without side effects. We have presented a targeted nanocarrier drug delivery system that can block the recruitment of inflammatory neutrophils, enabling specific inhibition of the core disease process and the potential to treat multiple diseases with a single drug. This represents a revolutionary treatment strategy for inflammatory diseases caused by inappropriate neutrophil activation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据